Revolution Medicines Q3 2024 Earnings Report $37.35 -0.75 (-1.97%) As of 04:00 PM Eastern Earnings HistoryForecast Revolution Medicines EPS ResultsActual EPS-$0.94Consensus EPS -$0.89Beat/MissMissed by -$0.05One Year Ago EPS-$0.99Revolution Medicines Revenue ResultsActual RevenueN/AExpected Revenue$0.35 millionBeat/MissN/AYoY Revenue GrowthN/ARevolution Medicines Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptRVMD Earnings History Remove Ads Revolution Medicines Earnings HeadlinesErasca initiated with an Outperform at Raymond JamesMarch 26 at 2:09 PM | markets.businessinsider.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from AnalystsMarch 23, 2025 | americanbankingnews.comTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at record pace. Why massive amounts of gold are being moved between countries. Why governments are repositioning their gold reserves. But here's what most people miss, the second pattern: During these resets, a unique anomaly appears in certain gold mining stocks. I call it the "Golden Anomaly."March 28, 2025 | Golden Portfolio (Ad)Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trialsMarch 14, 2025 | investing.comRevolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy NowMarch 3, 2025 | insidermonkey.comAnalysts Are Bullish on Top Healthcare Stocks: uniQure (QURE), Revolution Medicines (RVMD)March 3, 2025 | markets.businessinsider.comSee More Revolution Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revolution Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revolution Medicines and other key companies, straight to your email. Email Address About Revolution MedicinesRevolution Medicines (NASDAQ:RVMD), a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.View Revolution Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
